Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

First International Summit on Interventional Pharmacoeconomics

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Opportunities to Optimize Cancer Policies Panel Discussion

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

May

Today In Oncology

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Related Videos

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Opportunities to Optimize Cancer Policies Panel Discussion

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Plasma miR-371a-3p Predicts Recurrence in Stage I Testicular Cancer: Interim Results From the CLIMATE Study

Promising Signal Only ctDNA in Early Breast Cancer Not Yet Ready for Clinical Use

AI Pathology Framework for Biological Understanding of Tumors

AI Model Enables Earlier Detection of Pancreatic Cancer on Routine CT Scans

Breast Density Reduction: Endoxifen vs Tamoxifen